Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Group: NHANES LBXGLU: Fasting Glucose (mg/dL) Variable Definition

Generated Narrative: Group 282882

version: 4; Last updated: 2024-10-15 18:33:30+0000

Artifact Author: Brian S. Alper:

Artifact related artifact: No display for RelatedArtifact (type: cite-as; citation: NHANES LBXGLU: Fasting Glucose (mg/dL) Variable Definition [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 282882. Revised 2024-10-14. Available at: https://fevir.net/resources/Group/282882. Computable resource at: https://fevir.net/resources/Group/282882.)

url: https://fevir.net/resources/Group/282882

identifier: FEvIR Object Identifier/282882

title: NHANES LBXGLU: Fasting Glucose (mg/dL) Variable Definition

status: Active

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

description:

This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide.

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

membership: Conceptual

combinationMethod: All of

characteristic

code: Laboratory test

value: Fasting plasma glucose

exclude: false

characteristic

code: Unit of measure

value: mg/dL

exclude: false

characteristic

code: Method

value: Description of Laboratory Methodology - Glucose - In this enzymatic method glucose is converted to glucose-6-phosphate (G-6-P) by hexokinase in the presence of ATP, a phosphate donor. Glucose-6-phosphate dehydrogenase then converts the G-6-P to gluconate-6-P in the presence of NADP+. As the NADP+ is reduced to NADPH during this reaction, the resulting increase in absorbance at 340 nm (secondary wavelength = 700 nm) is measured. This is an endpoint reaction that is specific for glucose. Refer to the Laboratory Method Files section for a detailed description of the laboratory methods used. There were no changes to the lab site or lab method for this component in the NHANES 2017-2018 cycle. There were no changes to the lab equipment since 2015-2016. The Cobas C311 analyzer was used in 2017-2018 and 2015-2016. Refer to analytic note for changes to equipment in earlier survey cycles, which may impact analysis. Plasma Fasting Glucose Laboratory Procedure Manual (August 2020) https://wwwn.cdc.gov/nchs/data/nhanes/2017-2018/labmethods/GLU-J-MET-508.pdf

exclude: false